钇-90微球选择性内放射治疗用于局限性和局部晚期肝内胆管癌的治疗
本回顾性单中心研究纳入28例局限性肝内胆管癌患者,共行38次钇-90选择性内放射治疗,累积影像学缓解率57.1%,中位无进展生存期265天,中位生存期22.9个月,1年和3年生存率分别为78.4%和45.1%;10例(34.5%)经降期后接受手术,其总生存期更长(p=0.027)。作者认为该治疗安全有效,可考虑用于局限性和局部晚期肝内胆管癌。
要点
- 钇-90选择性内放射治疗局限性肝内胆管癌累积影像学缓解率达57.1%,中位无进展生存期265天。
- 全队列中位生存期22.9个月,1年和3年生存率分别为78.4%和45.1%。
- 10例(34.5%)降期后接受手术(7例切除、3例移植),其总生存期更长(p=0.027)。
核心结论
- 对于局限性和局部晚期肝内胆管癌,钇-90选择性内放射治疗在实现影像学缓解、降期至手术和移植以及导致病理坏死方面安全有效。
研究设计与样本
- 回顾性单中心研究,纳入28例连续性局限性肝内胆管癌患者,共行38次选择性内放射治疗(17次段性、13次叶性、8次联合给药),每次治疗平均优势靶剂量为238.4±130.0 Gy;采用Fine-Grey回归模型分析总生存期预测因素,并将桥接至手术的患者视为竞争事件。
诊断标准与关键数值
- 累积影像学缓解率为16/28(57.1%);中位无进展生存期265天;全队列中位生存期22.9个月,1年和3年生存率分别为78.4%和45.1%;接受手术患者1年和3年总生存率分别为100%和62.5%(95%CI:14.2-89.3%);年龄(p=0.028)、东部肿瘤协作组体能状态(p=0.030)和客观影像学缓解(p=0.014)与总生存期相关。
临床应用与阅片要点
- 作者在结论和临床相关性声明中提出,对于局限性和局部晚期肝内胆管癌患者应考虑选择性内放射治疗;年龄、东部肿瘤协作组体能状态和影像学缓解与生存相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate safety and effectiveness of selective internal radiation therapy (SIRT) using yttrium-90 for localized and locally advanced intrahepatic cholangiocarcinoma (iCCA).
METHODS: A retrospective review was performed of patients with localized iCCA treated with SIRT at a single institution. Overall survival (OS), local tumor response, progression-free survival (PFS), and toxicity were collected. Stratified analysis was performed based on surgical resection. Predictor analysis of OS was performed using the Fine-Grey regression analysis model with patients bridged to surgery regarded as competing events.
RESULTS: A total of 28 consecutive patients with localized iCCA were treated with a total of 38 sessions of SIRT (17 segmental, 13 lobar, and 8 combined deliveries) and a mean dominant target dose per session of 238.4 ± 130.0 Gy. The cumulative radiologic response rate was 16/28 (57.1%) with a median PFS of 265 days. Median survival time (MST) was 22.9 months for the entire cohort with 1-year and 3-year survival of 78.4% and 45.1%, respectively. Ten patients (34.5%) were downstaged to surgical intervention (7 resection, 3 transplant) and showed longer OS (p = 0.027). The 1-year and 3-year OS for patients who received surgery were 100% and 62.5% (95% CI: 14.2-89.3%), respectively. Age (p = 0.028), Eastern Cooperative Oncology Group performance status (p = 0.030), and objective radiologic response (p=0.014) are associated with OS. Two ≥grade 3 hyperbilirubinemia, anemia, and one pleuro-biliary fistula occurred post-SIRT.
CONCLUSIONS: SIRT for localized iCCA is safe and effective in achieving radiological response, downstaging to surgery and transplant, and resulting in pathologic necrosis.
CLINICAL RELEVANCE STATEMENT: Selective internal radiation therapy should be considered for patients with localized and locally advanced intrahepatic cholangiocarcinoma.
KEY POINTS: • The effectiveness of radioembolization for intrahepatic cholangiocarcinoma (iCCA) can be underestimated given the inclusion of extrahepatic disease. • Radioembolization is safe and effective for local and locally advanced iCCA. Age, Eastern Cooperative Oncology Group performance status, and radiologic response are associated with survival. • Radioembolization should be considered for patients with localized and locally advanced iCCA.
引用
- Yu Q, Ungchusri E, Pillai A, et al. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2023. PMID: 37812295. doi:10.1007/s00330-023-10203-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。